No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPAR[delta] and PPAR[gamma] act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma

Louise E. McGreavey; Faye Turner; Gillian Smith; Katherine Boylan; D. Timothy Bishop; David Forman; C. Roland Wolf; Jennifer H. Barrett

No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPAR[delta] and PPAR[gamma] act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma

Louise E. McGreavey, Faye Turner, Gillian Smith, Katherine Boylan, D. Timothy Bishop, David Forman, C. Roland Wolf, Jennifer H. Barrett

Research output: Contribution to journal › Article › peer-review

54 Citations (Scopus)

Abstract

Objectives Regular continuous non-steroidal anti-inflammatory drug (NSAID) use has been associated with a reduction in risk of colorectal cancer. Our objective was to investigate whether or not a number of the polymorphic genes involved in the metabolism of NSAIDs, including cytochrome P450s (CYPs), act as modifiers of this protective effect.

Methods As part of a multi-centre case-control study, 478 colorectal cancer patients and 733 controls (433 matched case-control pairs) answered questions on NSAID use. These individuals were then genotyped for common polymorphisms in P450 CYP2C8, P450 CYP2C9, UDP-glucuronosyl transferase (UGT)1A6 and peroxisome proliferator-activated receptor isoforms delta and gamma (PPAR delta and PPAR gamma).

Results and conclusion Our study confirmed the reduction in risk of colorectal cancer with regular NSAID use (odds ratio (OR)=0.73, 95% confidence interval (Cl) (0.56, 0.95)) but showed that none of the polymorphic genes studied appeared to modify the protective effect of regular NSAID use.

Original language	English
Pages (from-to)	713-721
Number of pages	9
Journal	Pharmacogenetics and Genomics
Volume	15
Issue number	10
Publication status	Published - 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://journals.lww.com/jpharmacogenetics/toc/2005/10000

Cite this

McGreavey, L. E., Turner, F., Smith, G., Boylan, K., Bishop, D. T., Forman, D., Wolf, C. R., & Barrett, J. H. (2005). No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPAR[delta] and PPAR[gamma] act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. Pharmacogenetics and Genomics, 15(10), 713-721. http://journals.lww.com/jpharmacogenetics/toc/2005/10000

@article{5029a33ca8fa44c4ae14e39c3fe2dbc9,

title = "No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPAR[delta] and PPAR[gamma] act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma",

abstract = "Objectives Regular continuous non-steroidal anti-inflammatory drug (NSAID) use has been associated with a reduction in risk of colorectal cancer. Our objective was to investigate whether or not a number of the polymorphic genes involved in the metabolism of NSAIDs, including cytochrome P450s (CYPs), act as modifiers of this protective effect.Methods As part of a multi-centre case-control study, 478 colorectal cancer patients and 733 controls (433 matched case-control pairs) answered questions on NSAID use. These individuals were then genotyped for common polymorphisms in P450 CYP2C8, P450 CYP2C9, UDP-glucuronosyl transferase (UGT)1A6 and peroxisome proliferator-activated receptor isoforms delta and gamma (PPAR delta and PPAR gamma).Results and conclusion Our study confirmed the reduction in risk of colorectal cancer with regular NSAID use (odds ratio (OR)=0.73, 95% confidence interval (Cl) (0.56, 0.95)) but showed that none of the polymorphic genes studied appeared to modify the protective effect of regular NSAID use.",

author = "McGreavey, {Louise E.} and Faye Turner and Gillian Smith and Katherine Boylan and Bishop, {D. Timothy} and David Forman and Wolf, {C. Roland} and Barrett, {Jennifer H.}",

year = "2005",

language = "English",

volume = "15",

pages = "713--721",

journal = "Pharmacogenetics and Genomics",

issn = "1744-6872",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

McGreavey, LE, Turner, F, Smith, G, Boylan, K, Bishop, DT, Forman, D, Wolf, CR & Barrett, JH 2005, 'No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPAR[delta] and PPAR[gamma] act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma', Pharmacogenetics and Genomics, vol. 15, no. 10, pp. 713-721. <http://journals.lww.com/jpharmacogenetics/toc/2005/10000>

No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPAR[delta] and PPAR[gamma] act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. / McGreavey, Louise E.; Turner, Faye; Smith, Gillian et al.
In: Pharmacogenetics and Genomics, Vol. 15, No. 10, 2005, p. 713-721.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPAR[delta] and PPAR[gamma] act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma

AU - McGreavey, Louise E.

AU - Turner, Faye

AU - Smith, Gillian

AU - Boylan, Katherine

AU - Bishop, D. Timothy

AU - Forman, David

AU - Wolf, C. Roland

AU - Barrett, Jennifer H.

PY - 2005

Y1 - 2005

N2 - Objectives Regular continuous non-steroidal anti-inflammatory drug (NSAID) use has been associated with a reduction in risk of colorectal cancer. Our objective was to investigate whether or not a number of the polymorphic genes involved in the metabolism of NSAIDs, including cytochrome P450s (CYPs), act as modifiers of this protective effect.Methods As part of a multi-centre case-control study, 478 colorectal cancer patients and 733 controls (433 matched case-control pairs) answered questions on NSAID use. These individuals were then genotyped for common polymorphisms in P450 CYP2C8, P450 CYP2C9, UDP-glucuronosyl transferase (UGT)1A6 and peroxisome proliferator-activated receptor isoforms delta and gamma (PPAR delta and PPAR gamma).Results and conclusion Our study confirmed the reduction in risk of colorectal cancer with regular NSAID use (odds ratio (OR)=0.73, 95% confidence interval (Cl) (0.56, 0.95)) but showed that none of the polymorphic genes studied appeared to modify the protective effect of regular NSAID use.

AB - Objectives Regular continuous non-steroidal anti-inflammatory drug (NSAID) use has been associated with a reduction in risk of colorectal cancer. Our objective was to investigate whether or not a number of the polymorphic genes involved in the metabolism of NSAIDs, including cytochrome P450s (CYPs), act as modifiers of this protective effect.Methods As part of a multi-centre case-control study, 478 colorectal cancer patients and 733 controls (433 matched case-control pairs) answered questions on NSAID use. These individuals were then genotyped for common polymorphisms in P450 CYP2C8, P450 CYP2C9, UDP-glucuronosyl transferase (UGT)1A6 and peroxisome proliferator-activated receptor isoforms delta and gamma (PPAR delta and PPAR gamma).Results and conclusion Our study confirmed the reduction in risk of colorectal cancer with regular NSAID use (odds ratio (OR)=0.73, 95% confidence interval (Cl) (0.56, 0.95)) but showed that none of the polymorphic genes studied appeared to modify the protective effect of regular NSAID use.

M3 - Article

SN - 1744-6872

VL - 15

SP - 713

EP - 721

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

IS - 10

ER -

No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPAR[delta] and PPAR[gamma] act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this